Prana Biotechnology Ltd (NASDAQ:PRAN) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

Prana Biotechnology (NASDAQ:PRAN) traded up 5.85% during trading on Friday, hitting $3.44. The stock had a trading volume of 555,616 shares. The company’s 50-day moving average is $2.76 and its 200 day moving average is $2.61. Prana Biotechnology has a 52 week low of $1.52 and a 52 week high of $4.58. The firm’s market cap is $5.10 million.

TRADEMARK VIOLATION NOTICE: “Prana Biotechnology Ltd (PRAN) Upgraded by ValuEngine to Sell” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at

About Prana Biotechnology

Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Prana Biotechnology Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology Ltd and related companies with's FREE daily email newsletter.